Will noninvasive glucose monitoring end in tears?

Controlling blood glucose levels within a normal range is the objective of diabetes management and will help to prevent long-term complications such as damages to the eye, kidneys and the nervous system and may also reduce the risk of cardiovascular events such as a heart attack or stroke. To achieve good glucose control in a safe manner without hypo- or hyperglycaemia, many patients with diabetes need to check their blood glucose level several times per day before making a treatment decision. The standard self-measurement requires patients to perform a finger prick with a lancet needle and measure the glucose content of the obtained capillary blood drop with a handheld glucose meter system. A patient diagnosed with diabetes type 1 at age 20 may easily have to perform more than 75.000 of these painful finger pricks during a lifetime, each causing a small injury to the skin.

Read More

Topics: The Science behind Diabetes, Clinical Trials in Diabetes

Posted by Dr. Eric Zijlstra on May 24, 2017 1:59:00 PM

Meet us at the MedTech Summit 2017


Focusing on Medical Technology, Mobile Health, Innovation Management, Regulatory Affairs, Diagnostics, Strategic Partnerships and Digitalization, the MedTech Summit 2017 congress will take place on June  21 and 22 in Nurnberg, Germany. 

Read More

Topics: Events

Posted by Tatiana Dicenzo on May 16, 2017 5:21:00 PM

First in Human (FIH) Trials: New draft guideline for Risk Mitigation

To provide best achievable clinical safety is always a challenge in first in human trials. Starting with the decision to proceed from preclinical research to the clinical development of a new drug researchers are confronted with many challenges including creating an appropriate study design, preparing the regulatory documents, conducting the clinical trial and, finally, drawing the right conclusions from the data.

Read More

Topics: Clinical Trials in Diabetes

Posted by Dr. Grit Andersen on May 16, 2017 3:40:00 PM

New Study about Sugar vs. Calorie-free Sweeteners

No influence of calorie-free drinks on total daily energy intake compared to sugar-sweetened drinks, recent study says

Worldwide, the incidence of obesity is increasing dramatically having more than doubled since 1980 [1]. Because obesity is associated with an array of metabolic pathologies, including cardiovascular disease, type 2 diabetes, musculoskeletal disorders, and even some cancers, identifying strategies that help regulate body weight is imperative.

Substituting nutritive sweeteners by non-nutritive sweeteners (NNS), including artificial and natural NNS, may have potential in facilitating weight control [2-4]. By preserving palatability despite having fewer calories than sugar, NNS could help to lower the energy density of beverages and foods, resulting in a lower total energy intake. However, recurring arguments indicate that NNS increase the appetite for sweet foods, promote overeating, and may even lead to weight gain[5-7]. In light of that, numerous studies in the past two decades have been performed to address these issues, with the overall question remaining: Do NNS help to reduce body weight?

Read More

Topics: The Science behind Diabetes, Treating Diabetes

Posted by Dr. Daniela Lamers on May 10, 2017 5:15:00 PM

InnoDiaCare: Summer School for Digital Innovation in Diabetes Care

Profil is proud to be part of the InnoDiaCare Summer School which is partnering with the CLOSE EIT Health innovation project on automated glucose control at home for patients with type 2 diabetes mellitus.

The InnoDiaCare Summer School for Digital innovation in Diabetes Care will be held in Poland (July) and in Germany (August). It is aimed at students and graduates to master their entrepreneurial skills and to empower them to create new business ideas on digital diabetes management.

Read More

Topics: Events

Posted by Prof. Dr. Freimut Schliess on May 5, 2017 5:00:00 PM

"Profil World" - The clinical diabetes research newsletter - April 2017

Dear Reader,

After a rainy winter, we are pleased to welcome Spring and send you our latest edition of "Profil World"- our newsletter packed with relevant news on diabetes and obesity research.

Read More

Topics: About Profil Germany

Posted by Tatiana Dicenzo on Apr 25, 2017 4:00:00 PM

Profil recent publications on diabetes

Profil scientists have already been busy in the first months of this year. So far we have published 15 papers (first-/senior- or co-authorship) in peer-reviewed journals addressing relevant aspects of pharmacokinetics and pharmacodynamics of novel antidiabetic drugs, medical device innovations and obesity treatments.

In this blog entry we provide a brief overview of 3 exciting publications.

Read More

Topics: The Science behind Diabetes, Clinical Trials in Diabetes

Posted by Tatiana Dicenzo on Apr 20, 2017 3:12:00 PM

How clinical trial results are distorted by reporting bias

Our perception of clinical trial outcomes may be distorted 

European and national legislation clearly specify the mandatory structure and content of a clinical trial protocol, e.g. for a randomised, controlled phase II human drug study [1-4]. The same applies to the structure and content of a clinical study report [5]. One should assume that a publication of a given clinical trial fulfilling these legal requirements is a high-quality and complete mirror of the trial protocol and the study report. The reality is different. Read on to learn more and discover what measures are being taken by the scientific community to avoid distorting public perception and reporting bias by implementing new rules on publishing results of clinical trials. 

Read More

Topics: Clinical Trials in Diabetes

Posted by Dr. Sabine Arnolds on Apr 13, 2017 5:00:00 PM

Your blood glucose meter might not be sufficiently accurate! (Update 03/2017)

Are blood glucose meters sufficiently accurate to detect hypoglycaemia?

A year ago Diabetes Care published our research letter [1] addressing the performance of current blood glucose meters (BGMs) in the low-glucose range. The initiative to write the letter was taken after studies showed considerable differences in performance in the low-glucose range between current BGMs [23].

Read More

Topics: Treating Diabetes

Posted by Dr. Eric Zijlstra on Apr 6, 2017 5:08:00 PM

How do SGLT2 inhibitors improve cardiovascular outcomes?

Cardiovascular (CV) events are the main cause of death among patients with type 2 diabetes mellitus (T2DM). Myocardial infarction and stroke are the macrovascular complications responsible for the high mortality in this collective of patients. The molecular mechanisms occurring in insulin resistant subjects (i.e. impaired insulin signalling through the phosphoinositol-3 kinase pathway with intact signalling through the mitogen-activated protein kinase pathway) directly contribute to the pathogenesis of atherosclerosis, independent of the concomitant metabolic abnormalities [1]. However, improvements in HbA1c take decades to impact CV risk profile [2], and as a matter of fact, the focus of several phase III studies investigating antidiabetic drugs is moving from the glucose control to the CV risk.

Read More

Topics: Clinical Trials in Diabetes

Posted by Dr. Jorge Arrubla on Mar 31, 2017 5:00:00 PM